Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers
ConclusionsProblems with the registration, design, analysis and reporting of clinical trials of nalmefene did not prevent it being licensed and recommended for treating alcohol dependence. This creates dilemmas for primary care clinicians and commissioning organisations where nalmefene has been heavily promoted, and poses wider questions about the effectiveness of the medicines regulation system and how to develop the alcohol treatment evidence base.
Source: Addiction - Category: Addiction Authors: Niamh Fitzgerald, Kathryn Angus, Andrew Elders, Marisa Andrade, Duncan Raistrick, Nick Heather, Jim McCambridge Tags: Vested Interests Series Source Type: research
More News: Addiction | Alcoholism | Clinical Trials | European Medicines Agency (EMA) | Health | Primary Care | Primary Care Practices | Study